Plus, a biotech with 'potentially game-changing' trial results, the 'too far, too fast' rally you might still be betting on, and more.
Oct 18, 2025
Nov 14, 2026
•
1 min read
Plus, why a Top 3% analyst at one of Wall Street’s biggest banks is still backing Nvidia...
Nov 7, 2026
Plus, a top-1% initiation on a battered AI networking chipmaker...
Nov 1, 2026
One stock pick from a top-ranked analyst with an implied upside of 100% or more.